Adalimumab biosimilar - Biocon/Mylan

Drug Profile

Adalimumab biosimilar - Biocon/Mylan

Alternative Names: BMO 2; MYL 1401A

Latest Information Update: 14 Jan 2016

Price : $50

At a glance

  • Originator Biocon
  • Developer Biocon; Mylan
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Autoimmune disorders; Plaque psoriasis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 10 Jun 2015 Phase-III clinical trials in Plaque psoriasis in Germany, Hungary (SC) (EudraCT2014-003420-46) after June 2015
  • 10 Jun 2015 Phase-III clinical trials in Plaque psoriasis in Estonia (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top